Zobrazeno 1 - 10
of 2 294
pro vyhledávání: '"B, Warren"'
Autor:
Richard B. Warren, Kerry Donnelly, Sandeep Kiri, Vanessa Taieb, Mahmoud Slim, Kyle Fahrbach, Binod Neupane, Marissa Betts, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3133-3147 (2024)
Abstract Introduction Biologic treatments have made complete skin clearance in moderate to severe plaque psoriasis a real possibility. Although clinical trials demonstrated the superiority of bimekizumab over secukinumab, adalimumab, and ustekinumab,
Externí odkaz:
https://doaj.org/article/1b8b5aa9d0874f258cc203e0740e4093
Autor:
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B. Gottlieb
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 11, Pp 720-731 (2024)
Objective The objective of this study was to assess 52‐week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/−MTX) treatment at baseline. Methods We conducted a post
Externí odkaz:
https://doaj.org/article/9bc82b35361540eca261704dc88423d0
Autor:
A. L. Doran, V. Dutch, B. Warren, R. A. Watson, K. Murphy, A. Aldis, I. Cooper, C. Cockram, D. Harp, M. Desmau, L. Keppler
Publikováno v:
Geoscience Communication, Vol 7, Pp 227-244 (2024)
The past decade has seen a global transformation in how we communicate and connect with one another, making it easier to network and collaborate with colleagues worldwide. The COVID-19 pandemic led to a rapid and unplanned shift toward virtual platfo
Externí odkaz:
https://doaj.org/article/c453c98988974705b045146b7d54a359
Autor:
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2841-2857 (2024)
Abstract Introduction With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, par
Externí odkaz:
https://doaj.org/article/87932ef0b7d34aacbbdc912e39e468f6
Autor:
Bernhard Korge, Olivier Vanhooteghem, Charles W. Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B. Warren
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2923-2926 (2024)
Externí odkaz:
https://doaj.org/article/99b0aed743ab47f79d535ed54575f5a4
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1413-1423 (2024)
Abstract Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriat
Externí odkaz:
https://doaj.org/article/4262254099cb40d39645fcfe05396997
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1403-1412 (2024)
Abstract Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis fact
Externí odkaz:
https://doaj.org/article/ce35de981e1147979941d6203e2e5191
Autor:
Luis Puig, Antonio Costanzo, Elke M. G. J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2539-2558 (2024)
Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clini
Externí odkaz:
https://doaj.org/article/ab526a4a99574512a77a238ef4a81a03
Autor:
Bernhard Korge, Olivier Vanhooteghem, Charles W. Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B. Warren
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2077-2092 (2024)
Abstract Introduction Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this stu
Externí odkaz:
https://doaj.org/article/9b8405ecefbc478e911d59e7b2e3c3c1
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 817-828 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-m
Externí odkaz:
https://doaj.org/article/f5c52a1be9d64789923ca497a0e9b3a0